VERTEX PHARMACEUTICALS INC / MA (VRTX) Insider Transactions
Over the last 12 months, 22 VERTEX PHARMACEUTICALS INC / MA (VRTX) insiders filed 222 SEC Form 4 transactions — $5.8M in open-market purchases ( 2 distinct buyers) and $158.5M in open-market sales. 7% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $5.8MOpen-market buys (1y)
- $158.5MOpen-market sells (1y)
- 22Distinct insiders
- 222Transactions filed
- 7%Under Rule 10b5-1 plan
- 2026-07-21Latest filing
Recent Form 4 Filings Most recent 50 of 222 (1-year window)
Each row is a single Form 4 filing event for VRTX, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.
| Date | Insider | Title | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-07-21 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Grant | A | $0 | 8,251 | $0.0 |
| 2026-07-21 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Grant | A | $0 | 8,251 | $0.0 |
| 2026-07-15 | SACHS BRUCE I | — | Grant | A | $47.5K | 100 | $475.3 |
| 2026-07-15 | Garber Alan M | — | Grant | A | $15.0K | 32 | $475.3 |
| 2026-07-02 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sell 10b5-1 | S | $787.5K | 1,500 | $525.0 |
| 2026-07-02 | McKechnie Duncan | EVP, Chief Commercial Officer | Sell 10b5-1 | S | $799.8K | 1,541 | $519.0 |
| 2026-07-01 | Liu Joy | EVP and Chief Legal Officer | Sell 10b5-1 | S | $416.2K | 828 | $502.7 |
| 2026-06-26 | Bozic Carmen | EVP and CMO | Sell 10b5-1 | S | $287.6K | 596 | $482.5 |
| 2026-06-18 | Bozic Carmen | EVP and CMO | Sell 10b5-1 | S | $471.4K | 1,020 | $462.2 |
| 2026-06-15 | Bozic Carmen | EVP and CMO | Sell 10b5-1 | S | $1.8M | 4,062 | $450.0 |
| 2026-06-05 | Bozic Carmen | EVP and CMO | Sell 10b5-1 | S | $785.3K | 1,745 | $450.0 |
| 2026-06-01 | Liu Joy | EVP and Chief Legal Officer | Sell 10b5-1 | S | $364.2K | 828 | $439.9 |
| 2026-05-29 | Bozic Carmen | EVP and CMO | Sell 10b5-1 | S | $888.3K | 1,974 | $450.0 |
| 2026-05-15 | Bunnage Mark E. | EVP, Chief Scientific Officer | Sell 10b5-1 | S | $15.0K | 33 | $453.4 |
| 2026-05-15 | Bozic Carmen | EVP and CMO | Sell 10b5-1 | S | $614.0K | 1,354 | $453.4 |
| 2026-05-12 | Bozic Carmen | EVP and CMO | Sell 10b5-1 | S | $3.1M | 6,988 | $450.0 |
| 2026-05-04 | Bhatia Sangeeta N. | — | Sell 10b5-1 | S | $134.7K | 318 | $423.7 |
| 2026-05-01 | Upadhyay Suketu | — | Grant | A | $0 | 2,866 | $0.0 |
| 2026-05-01 | Upadhyay Suketu | — | Grant | A | $0 | 796 | — |
| 2026-05-01 | Thornberry Nancy | — | Grant | A | $0 | 472 | $0.0 |
| 2026-05-01 | Thornberry Nancy | — | Grant | A | $0 | 1,433 | $0.0 |
| 2026-05-01 | Thornberry Nancy | — | Grant | A | $0 | 398 | — |
| 2026-05-01 | Schneider Jennifer | — | Grant | A | $0 | 472 | $0.0 |
| 2026-05-01 | Schneider Jennifer | — | Grant | A | $0 | 1,433 | $0.0 |
| 2026-05-01 | Schneider Jennifer | — | Grant | A | $0 | 796 | — |
| 2026-05-01 | SACHS BRUCE I | — | Grant | A | $0 | 2,866 | $0.0 |
| 2026-05-01 | MCKENZIE DIANA | — | Grant | A | $0 | 943 | $0.0 |
| 2026-05-01 | MCKENZIE DIANA | — | Grant | A | $0 | 796 | — |
| 2026-05-01 | Lagarde Michel | — | Grant | A | $0 | 2,866 | $0.0 |
| 2026-05-01 | Garber Alan M | — | Grant | A | $0 | 472 | $0.0 |
| 2026-05-01 | Garber Alan M | — | Grant | A | $0 | 1,433 | $0.0 |
| 2026-05-01 | CARNEY LLOYD | — | Grant | A | $0 | 2,866 | $0.0 |
| 2026-05-01 | Bhatia Sangeeta N. | — | Grant | A | $0 | 943 | $0.0 |
| 2026-05-01 | Upadhyay Suketu | — | Sell | D | $0 | 796 | — |
| 2026-05-01 | Thornberry Nancy | — | Sell | D | $0 | 398 | — |
| 2026-05-01 | Schneider Jennifer | — | Sell | D | $0 | 796 | — |
| 2026-05-01 | MCKENZIE DIANA | — | Sell | D | $0 | 796 | — |
| 2026-05-01 | Liu Joy | EVP and Chief Legal Officer | Sell 10b5-1 | S | $469.2K | 1,104 | $425.0 |
| 2026-04-15 | Upadhyay Suketu | — | Grant | A | $35.6K | 81 | $442.5 |
| 2026-04-15 | SACHS BRUCE I | — | Grant | A | $47.5K | 107 | $442.5 |
| 2026-04-15 | Garber Alan M | — | Grant | A | $15.0K | 34 | $442.5 |
| 2026-04-01 | Liu Joy | EVP and Chief Legal Officer | Sell 10b5-1 | S | $439.3K | 978 | $449.2 |
| 2026-03-27 | Bozic Carmen | EVP and CMO | Sell 10b5-1 | S | $1.1M | 2,329 | $450.9 |
| 2026-03-13 | Bozic Carmen | EVP and CMO | Sell | — | $1.1M | 2,329 | $481.8 |
| 2026-03-11 | McKechnie Duncan | EVP, Chief Commercial Officer | Sell | — | $1.3M | 2,633 | $498.4 |
| 2026-03-04 | McKechnie Duncan | EVP, Chief Commercial Officer | Sell | — | $1.2M | 2,437 | $475.3 |
| 2026-03-02 | Liu Joy | EVP and Chief Legal Officer | Sell | — | $442.4K | 892 | $496.0 |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | — | $191.9K | 400 | $479.8 |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | — | $57.8K | 120 | $481.5 |
| 2026-02-27 | Kewalramani Reshma | CEO & President | Sell | — | $115.9K | 240 | $482.8 |
Showing the most recent 50 of 222 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.
Top Insider Buyers of VRTX By dollar volume, 1-year window
- Kewalramani Reshma $3.9M
- SACHS BRUCE I $1.9M
Methodology & FAQ
How We Track VRTX Insider Transactions
Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.
What is an SEC Form 4 filing for VERTEX PHARMACEUTICALS INC / MA?
Form 4 is a transaction-level disclosure that corporate insiders — officers, directors, and beneficial owners of more than 10% of a registered class of equity securities — must file with the SEC within two business days of any change in their beneficial ownership of VERTEX PHARMACEUTICALS INC / MA (VRTX) shares.
What is a Rule 10b5-1 trading plan?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.
How is "insider buying" different from a stock grant or option exercise?
An insider buy (SEC transaction code P) is an open-market purchase of VERTEX PHARMACEUTICALS INC / MA (VRTX) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.
How recent is the data?
Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.